Juno Therapeutics Inc  

(Public, NASDAQ:JUNO)   Watch this stock  
Find more results for JUNO
+0.31 (0.71%)
Oct 20 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 42.70 - 44.10
52 week 17.52 - 47.03
Open 43.27
Vol / Avg. 1.89M/2.26M
Mkt cap 4.88B
P/E     -
Div/yield     -
EPS -2.83
Shares 106.32M
Beta     -
Inst. own 78%
Nov 7, 2017
Q3 2017 Juno Therapeutics Inc Earnings Release (Estimated) - 4:00PM EST - Add to calendar
Sep 12, 2017
Juno Therapeutics Inc at Morgan Stanley Healthcare Conference - Webcast
Sep 7, 2017
Juno Therapeutics Inc at Citi Biotech Conference - Webcast
Aug 15, 2017
Juno Therapeutics Inc at Wedbush PacGrow Healthcare Conference - Webcast
Aug 3, 2017
Q2 2017 Juno Therapeutics Inc Earnings Call
Aug 3, 2017
Q2 2017 Juno Therapeutics Inc Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q2 (Jun '17) 2016
Net profit margin -473.67% -309.47%
Operating margin -486.36% -329.02%
EBITD margin - -304.22%
Return on average assets -31.28% -17.58%
Return on average equity -41.37% -22.13%
Employees 554 -
CDP Score - -


400 Dexter Ave N Ste 1200
SEATTLE, WA 98109-4703
United States - Map
+1-206-5821600 (Phone)
+1-302-6365454 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Juno Therapeutics, Inc. (Juno) is a biopharmaceutical company, which is focused on developing cellular immunotherapies for the treatment of cancer. The Company is developing cell-based cancer immunotherapies based on its chimeric antigen receptor (CAR) and T cell receptor (TCR) technologies to genetically engineer T cells to recognize and kill cancer cells. Its product candidates JCAR017, JCAR014, and JCAR015, as well as an additional early stage product candidate incorporating a fully human binding domain, leverage CAR technology to target CD19, a protein expressed on the surface of almost all B cell leukemias and lymphomas. Its CAR product candidate JCAR018 targets CD22, a different protein commonly expressed on the surface of B cell leukemias and lymphomas. Its MUC-16 directed product candidate is an armored CAR that secretes the cytokine interleukin 12 (IL-12), which may help to overcome the inhibitory effects that the tumor microenvironment can have on T cell activity.

Officers and directors

Howard H. Pien Independent Chairman of the Board
Age: 59
Bio & Compensation  - Reuters
Hans Edgar Bishop President, Chief Executive Officer, Director
Age: 52
Bio & Compensation  - Reuters
Sunil Agarwal M.D. President of Research & Development
Age: 47
Bio & Compensation  - Reuters
Steven D. Harr M.D. Chief Financial Officer, Head of Corporate Development
Age: 46
Bio & Compensation  - Reuters
Hyam I. Levitsky M.D Executive vice president - Research, chief scientific officer
Age: 54
Bio & Compensation  - Reuters
Robert W. Azelby Executive Vice President, Chief Commercial Officer
Age: 49
Bio & Compensation  - Reuters
Bernard J. Cassidy General Counsel, Secretary
Age: 62
Bio & Compensation  - Reuters
Hal V. Barron M.D. Independent Director
Age: 54
Bio & Compensation  - Reuters
Jay T. Flatley Director
Age: 64
Bio & Compensation  - Reuters
Richard Klausner M.D. Director
Age: 65
Bio & Compensation  - Reuters